Brain cancer funding should be directed towards more ambitious innovations rather than just research that is making incremental improvements to existing survival prospects, a review of the Australian Brain Cancer Mission has found.
The review, released in December [link here], said more early investment in basic research was needed to create a pipeline to feed future clinical trials, considering the typically long timeframes before impacts were felt.
The Australian Brain Cancer Mission, launched by the former government in 2017, has a co-funded $137 million investment to support brain cancer research. It aims to double survival rates and improve quality of life over the next decade to 2027.
Encouragingly, the final report delivered at the halfway mark of the Mission’s 10-year deadline found the Mission had provided more Australians with access to clinical trials and had built additional capacity for more clinical trials in the future.
Researchers indicated that about 1350 additional patients were given access to a clinical trial that they otherwise would not have had, and enhanced capacity would likely lead to 70 additional trial sites over the next five years.
Based on interviews, increased funding for brain cancer research had also led to more brain cancer researchers, some of whom had transitioned from other fields, such as liver and lung cancer, perhaps as a result of improved financial certainty.
“The security of funding provided by the Mission to clinical trials has already started to allow researchers to seek out international trials more efficiently,” said the authors of the review, which was undertaken by the Centre for International Economics.
“As funding is secured, researchers can focus on applying to the trial immediately, as opposed to discovering the trial, then raising funds, then applying. Particularly for paediatrics, where often the best treatments can only be accessed via clinical trials, this certainty of funding has been critical.”
However, the report pointed out that it was too early to definitively say what impact the Medical Research Future Fund (MRFF) grants would have on new health technologies and interventions, although the prospects were positive.